Abstract
Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have